Atomo Diagnostics Ltd. (AT1) AI Stock Analysis

• Market Cap: AU$29.98M
• Dividend Yield: N/A
• Average Volume (3M): 1.80M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: -7.20%
• EPS Growth: 28.70%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 810,175,300
• 10 Day Avg. Volume: 984,499
• 30 Day Avg. Volume: 1,797,539
• PEG Ratio: 0.06
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 2.39
• P/FCF Ratio: -4.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: AU$0.04 ▼(-7.50% Downside)

The score is primarily held back by weak financial performance (revenue decline, large losses, and negative operating/free cash flow). Technicals provide partial support with an improving trend versus longer-term moving averages and moderately positive momentum. Valuation contributes negatively due to negative earnings (making P/E less meaningful) and no dividend yield data.

Positive Factors

Low Leverage

Minimal leverage enhances financial stability, providing Atomo Diagnostics with flexibility to navigate financial challenges and invest in growth opportunities without the burden of high interest obligations.

Stable Capital Structure

A stable capital structure supports long-term sustainability, allowing Atomo to maintain operations and potentially secure favorable financing terms if needed.

Product Innovation

Focusing on innovative diagnostic solutions positions Atomo as a key player in the growing healthcare sector, potentially driving future revenue growth through product adoption.

Negative Factors

Declining Revenues

Declining revenues indicate challenges in market penetration and product demand, which could hinder long-term growth and profitability unless addressed strategically.

Negative Profitability

Persistent negative profitability undermines financial health, limiting the ability to reinvest in business expansion and innovation, potentially impacting competitive positioning.

Cash Flow Challenges

Negative cash flow constrains operational flexibility and investment capacity, necessitating strategic improvements to ensure liquidity and support future growth initiatives.

Atomo Diagnostics Ltd. Business Overview & Revenue Model

Company Description

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. It offers rapid diagnostic test devices for COVID-19, HIV screening, pregnancy test, and respiratory test. The company was incorporated in 2010 and is headquartered in Leichhardt, Australia.

How the Company Makes Money

Atomo Diagnostics generates revenue primarily through the sale of its diagnostic devices and test kits to healthcare providers, laboratories, and distributors. The company operates on a B2B model, securing contracts and partnerships with healthcare organizations and governments to supply its products. Additionally, Atomo may engage in collaborations with pharmaceutical companies to develop tailored diagnostic solutions, which can further enhance its revenue streams. Key partnerships and licensing agreements are significant contributors to its earnings, providing Atomo with a stable income from both product sales and potential royalties from its proprietary technology.

Atomo Diagnostics Ltd. Financial Statement Overview

Summary

Atomo Diagnostics Ltd. is facing significant financial challenges, with declining revenues and persistent losses impacting profitability. The balance sheet remains relatively stable with low leverage, but the negative return on equity and cash flow issues underscore the need for strategic improvements. The company must focus on reversing revenue declines and improving operational efficiency to enhance financial health.

Income Statement

Atomo Diagnostics Ltd. has faced declining revenues with a negative revenue growth rate of -10.04% in the most recent year. The company is struggling with profitability, as indicated by negative margins across the board, including a net profit margin of -131.08% and an EBIT margin of -153.90%. Despite a slight improvement in gross profit margin to 47.28%, the overall financial health of the income statement remains weak.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.03, indicating minimal leverage, which is a positive aspect. However, the return on equity is significantly negative at -71.26%, reflecting poor profitability and returns for shareholders. The equity ratio stands at a healthy level, suggesting a stable capital structure despite ongoing losses.

Cash Flow

Cash flow analysis reveals challenges with negative operating cash flow and free cash flow, although the free cash flow to net income ratio is slightly above 1, indicating some alignment between cash flow and accounting profits. However, the free cash flow growth rate is negative at -44.42%, highlighting cash flow deterioration.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.79M	3.79M	4.09M	2.54M	12.34M	6.72M
Gross Profit	1.79M	1.79M	1.44M	-6.08M	-1.85M	-1.71M
EBITDA	-4.69M	-4.69M	-6.12M	-9.00M	-4.72M	-4.70M
Net Income	-4.97M	-4.97M	-6.85M	-9.96M	-5.71M	-6.02M
Balance Sheet
Total Assets	9.28M	9.28M	11.38M	16.47M	26.62M	32.24M
Cash, Cash Equivalents and Short-Term Investments	3.22M	3.22M	3.69M	6.47M	12.97M	17.95M
Total Debt	185.10K	185.10K	84.67K	254.88K	340.81K	67.59K
Total Liabilities	2.30M	2.30M	1.29M	1.68M	1.81M	2.15M
Stockholders Equity	6.98M	6.98M	10.08M	14.79M	24.81M	30.09M
Cash Flow
Free Cash Flow	-1.99M	-1.99M	-4.70M	-6.25M	-5.11M	-10.12M
Operating Cash Flow	-1.96M	-1.96M	-4.69M	-5.85M	-2.81M	-4.23M
Investing Cash Flow	-33.89K	-33.89K	-16.08K	-401.28K	-2.31M	-5.90M
Financing Cash Flow	1.46M	1.46M	1.87M	-170.75K	17.61K	997.37K

Atomo Diagnostics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AT1, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 56.32 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:AT1.

Atomo Diagnostics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CBL	51 Neutral	AU$24.72M	-2.58	-103.74%	―	14.84%	39.64%
AT1	48 Neutral	AU$29.98M	-4.81	-58.27%	―	-7.20%	28.70%
HMD	43 Neutral	AU$42.81M	-7.69	-513.22%	―	-34.06%	75.47%
IRX	43 Neutral	AU$5.91M	-3.87	―	―	―	-55.00%
UCM	39 Underperform	AU$3.12M	-0.91	-218.52%	―	-30.80%	-38.95%
ADR	37 Underperform	AU$24.52M	-0.64	-1476.79%	―	-2.82%	32.47%

Atomo Diagnostics Ltd. Corporate Events

Atomo Diagnostics Grants Options to Director Following Shareholder Approval

Atomo Diagnostics Ltd. announced a change in the director’s interest, confirming the issuance of 1,000,000 unlisted options exercisable at $0.0115, expiring on June 30, 2028, to director Cheri Walker following shareholder approval. This grant highlights the company’s strategy to align leadership incentives with long-term stakeholder value creation.

The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.

Atomo Diagnostics Issues New Equity Securities Under Employee Incentive Scheme

Atomo Diagnostics Ltd. has announced the issuance of 3,100,000 unquoted equity securities in the form of options expiring on June 30, 2028, with an exercise price of $0.0115. This issuance is part of an employee incentive scheme and is not intended to be quoted on the ASX. The move is likely aimed at motivating and retaining key personnel, potentially impacting the company’s operational efficiency and market competitiveness.

The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.

Atomo Diagnostics Addresses ASX Query on Unusual Trading Activity

Atomo Diagnostics Ltd. has responded to an ASX query regarding unusual trading activity in its securities, confirming it is unaware of any undisclosed price-sensitive information that could explain the recent changes in price and volume. The company asserts its compliance with ASX Listing Rules, specifically Rule 3.1, and states that its board has authorized the response.

The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.

Atomo Diagnostics Adopts Amended Constitution

Atomo Diagnostics Ltd. announced the adoption of an amended constitution, as approved by its shareholders at the recent Annual General Meeting. This change reflects the company’s ongoing commitment to aligning its governance framework with its operational and strategic objectives, potentially impacting its market positioning and stakeholder engagement.

Atomo Diagnostics Reports Successful 2025 AGM Results

Atomo Diagnostics Limited announced the results of its 2025 Annual General Meeting, where all resolutions were passed by a poll. This announcement indicates a smooth decision-making process and reflects the company’s adherence to regulatory requirements, potentially strengthening stakeholder confidence.

Atomo Diagnostics Highlights Strategic Focus at 2025 AGM

Atomo Diagnostics Ltd. has released the MD & CEO’s address for their 2025 Annual General Meeting, highlighting the company’s ongoing commitment to innovation in the rapid diagnostic testing sector. This announcement underscores Atomo’s strategic focus on enhancing its market position by delivering cutting-edge diagnostic solutions, which is expected to positively impact its operations and stakeholder engagement.

Atomo Diagnostics Advances in Rapid Testing Amid Industry Challenges

Atomo Diagnostics Ltd. has made significant strides in the past year despite challenges in the global diagnostics sector. The company has advanced commercial partnerships, expanded international regulatory approvals, streamlined operations, and focused on high-value opportunities in infectious disease and rapid test applications. These efforts align with the growing trend towards decentralised, at-point-of-care, and self-testing solutions, reinforcing Atomo’s position in the market.

Atomo Diagnostics Reports Significant Progress and Expansion in Q1 FY26

Atomo Diagnostics Ltd. has made significant commercial progress in Q1 FY26, highlighted by the submission of the FebriDx test for a CLIA waiver with the US FDA, following successful validation of the Pascal platform in clinical trials. The company has received substantial purchase orders from Lumos, totaling approximately $1 million, as part of their FebriDx agreement. Atomo’s HIV self-test has expanded its distribution channels, launching on Chemist Warehouse’s ecommerce site in Australia and receiving orders from USAID for Ukraine. Additionally, Atomo has secured $1.3 million in new capital to support ongoing business objectives, with a reported revenue of $680k for the quarter.

Atomo Diagnostics to Release Q1 FY26 Results and Host Investor Webinar

Atomo Diagnostics Limited announced it will release its Q1 FY26 results on October 29, 2025, followed by a webinar hosted by Managing Director & CEO, John Kelly. This announcement highlights Atomo’s ongoing commitment to transparency and engagement with analysts and investors, potentially impacting its market positioning and stakeholder relations positively.